Listing 7.18 Repeated Complications of Hematological Disorders in 2026: The Catch-All Rule That Rescues Anemias and Marrow Failure Cases Without Enough Hospitalizations to Meet 7.05 or 7.08

Most Blue Book Section 7 hematology listings ask for a specific event count. Listing 7.05 for sickle cell disease wants six painful crises in 12 months or three hospitalizations or a hemoglobin at or below 7 measured three times a year. Listing 7.08 for thrombosis and hemostasis wants three hospitalizations lasting 48 hours or more inside a 12 month window. Both are hard bars for anyone whose disease is chronic and grinding rather than crisis prone. Listing 7.18 exists for that exact person. It says your hematological disorder does not need to look like a countable series of ER visits. It just needs to keep interrupting your ability to live, in a way that is documented, repeated, and severe enough to cause a marked limitation in one of three functional areas. Once you understand the math inside 7.18, you can rescue cases that look impossible under 7.05 or 7.08.

Where 7.18 Sits in Section 7

Section 7.00 of Appendix 1 to Subpart P of Part 404 covers hematological disorders. The specific listings are 7.05 sickle cell disease and beta thalassemia, 7.08 disorders of thrombosis and hemostasis, 7.10 disorders of bone marrow failure, and 7.17 hematological disorders treated by bone marrow or stem cell transplantation. Listing 7.18 is the closer. It captures repeated complications of any hematological disorder that has not been captured by the other rules, provided the frequency, duration, and functional loss meet the specific tests written into 7.18.

The catch all structure is deliberate. SSA cannot list every hematological disorder in the Blue Book. Bone marrow failure syndromes alone include Fanconi anemia, Diamond Blackfan anemia, Shwachman Diamond syndrome, dyskeratosis congenita, congenital amegakaryocytic thrombocytopenia, GATA2 deficiency, SAMD9 and SAMD9L syndromes, telomere biology disorders, and paroxysmal nocturnal hemoglobinuria. Add pernicious anemia, chronic autoimmune hemolytic anemia, cold agglutinin disease, warm antibody hemolytic anemia, chronic ITP, refractory thrombocytopenia purpura, chronic granulomatous forms of myelodysplastic syndrome, low grade myelofibrosis, aplastic anemia off transplant, and the list only grows. Listing 7.18 gives a route for any of these when the clinical picture fits.

The Exact Definition of Repeated Complications

Section 7.00G3 defines repeated complications with a three way test. Your complications qualify as repeated when any one of the following patterns is present:

1. Complications occur on an average of three times a year, or once every four months, each lasting two weeks or more.
2. Complications do not last for two weeks each but occur substantially more frequently than three times in a year or once every four months.
3. Complications occur less frequently than three times a year or once every four months, but last substantially longer than two weeks each.

The three way test is a frequency and duration trade off. If your complications are long, you need fewer. If your complications are short, you need more. The rule text is designed to catch the person whose disease keeps them out of function without following a predictable schedule.

The rule also says the required number of complications must occur within the period being considered in connection with your application or continuing disability review. That means the analyst looks at your entire relevant period, not just the last 12 months, when deciding whether the frequency test is met. This helps claimants whose worst year happened before they filed.

Same or Different Complications Both Count

Section 7.00G3 also says your impairment will satisfy the criterion regardless of whether you have the same kind of complication repeatedly, all different complications, or any combination. Two hemolytic crises and one transfusion reaction together count. A DVT plus a pulmonary embolism plus a bleeding gum episode together count. This is critical for polycomplication diseases like PNH, where you might have thrombosis, hemolysis, and bone marrow failure symptoms in the same year.

The Three Marked-Limitation Areas

Frequency alone is not enough. Section 7.00G4 requires that your hematological disorder cause a marked limitation in one of three general areas of functioning:

• Activities of daily living. These include cleaning, shopping, cooking, taking public transportation, paying bills, maintaining a residence, caring for hygiene, using telephones and directories, and using a post office.
• Social functioning. Your ability to interact independently, appropriately, effectively, and on a sustained basis with other individuals.
• Concentration, persistence, or pace. Your ability to sustain focus, attention, and concentration long enough to permit the timely and appropriate completion of tasks commonly found in work settings.

Marked means more than moderate but less than extreme. It means your functioning in that area is seriously interfered with. You do not need marked in all three. One is enough.

Section 7.00G4 also says functional limitations may result from the disease process itself, from mental functioning changes, from physical functioning changes, or from any combination. This matters for anemia cases where fatigue and cognitive slowing dominate. Chronic anemia causes measurable cognitive changes, and the rule text authorizes the analyst to consider both physical and mental limitations together.

Comparing 7.18 to 7.05 and 7.08

7.05 sickle cell disease and beta thalassemia

Listing 7.05A requires six documented painful crises within 12 months, each requiring IV or IM narcotic medication and each at least 30 days apart. Listing 7.05B requires three hospitalizations within 12 months each 30 days apart and each lasting at least 48 hours. Listing 7.05C requires hemoglobin at or below 7 measured at least three times a year, at least 30 days apart. These are hard event counts.

7.18 becomes the fallback for sickle cell patients who are chronic but not crisis prone. If you have avascular necrosis of both hips from sickle disease, chronic bone pain requiring daily opioids, and cannot do household tasks or hold conversations because of pain and fatigue, you may meet 7.18 through marked limitation in ADLs even if you did not have six documented crises in 12 months.

7.08 thrombosis and hemostasis

Listing 7.08 requires three hospitalizations within 12 months for complications like uncontrolled bleeding or thromboses, each at least 30 days apart, and each lasting at least 48 hours including ER hours immediately before admission. Many bleeding disorder patients manage complications at home with factor concentrates and never hit three hospitalizations even when they are severely limited.

7.18 becomes the fallback for hemophilia patients on factor prophylaxis whose joint disease from repeated bleeds is disabling, for chronic ITP patients whose fatigue and easy bruising limit function, and for von Willebrand disease patients with menorrhagia so severe they cannot leave the house 8 days a month.

7.10 bone marrow failure disorders

Listing 7.10 requires either recurrent complications requiring three or more hospitalizations in 12 months, each 30 days apart and 48 hours or more, or specific transfusion or infection thresholds. Similar structure to 7.05B and 7.08.

7.18 catches marrow failure patients whose disease is stable but chronically debilitating. Someone on chronic transfusion support for MDS every three weeks may not hit hospitalizations but cannot maintain a work schedule around transfusion days and post transfusion fatigue.

Common Diagnoses That Fit 7.18 Best

Pernicious Anemia

Pernicious anemia does not have its own Blue Book listing. When B12 deficiency causes chronic macrocytic anemia, subacute combined degeneration of the spinal cord, peripheral neuropathy, cognitive slowing, and cardiac symptoms, patients can meet 7.18 through marked limitation in ADLs from fatigue and neurological deficits, marked limitation in concentration from B12 deficiency cognitive changes, or both. Documentation should include serum B12, methylmalonic acid, homocysteine, intrinsic factor antibodies, parietal cell antibodies, Schilling test if available, MRI showing subacute combined degeneration if present, and neuropsych testing.

Aplastic Anemia Off Transplant

Aplastic anemia patients on immunosuppression with ATG and cyclosporine, or on eltrombopag, who did not proceed to stem cell transplant, often cycle in and out of pancytopenia. Repeated infections, transfusion dependence, and profound fatigue are the norm. 7.18 fits when the complications include transfusion reactions, febrile neutropenic events, opportunistic infections, and hemorrhagic events over a documented multi year period.

Myelodysplastic Syndrome

Lower risk MDS with symptomatic anemia requiring red cell transfusion every three to four weeks, plus iron chelation for chronic iron overload, meets 7.18 in most cases through marked limitation in ADLs from fatigue and marked limitation in concentration. Higher risk MDS on hypomethylating agents like azacitidine or decitabine adds cyclic bone marrow suppression that limits function during and after each treatment cycle.

Paroxysmal Nocturnal Hemoglobinuria

PNH patients on eculizumab or ravulizumab have complement blockade that controls intravascular hemolysis and thrombosis risk, but breakthrough hemolysis, cyclical crises, and residual bone marrow failure remain problems. Patients not on complement inhibitors have very high thrombosis rates and chronic anemia. 7.18 captures both groups when frequency and functional loss meet the tests.

Autoimmune Hemolytic Anemia

Warm antibody AIHA, cold agglutinin disease, and mixed autoimmune hemolytic anemia can be chronic and relapsing. Rituximab, corticosteroids, splenectomy, and complement inhibitors like sutimlimab help but relapses are common. Chronic anemia below 10 with intermittent transfusion requirements, plus fatigue and cardiac symptoms, often meets 7.18.

Chronic Immune Thrombocytopenia

ITP patients with platelet counts chronically below 30,000, on second and third line therapies including TPO receptor agonists, splenectomy, rituximab, or fostamatinib, often have persistent bleeding symptoms and cannot work in any job with a fall risk or a cut risk. Documentation should include CBCs across the relevant period, bone marrow biopsy if performed, and treatment response records.

Rare Marrow Failure Syndromes

Fanconi anemia, Diamond Blackfan anemia, Shwachman Diamond syndrome, dyskeratosis congenita, telomere biology disorders, and GATA2 deficiency have distinct clinical courses. Section 7.18 accepts any of these when repeated complications and marked functional loss are documented. Genetic testing is helpful for diagnosis but not required by 7.18 itself.

Building the 12-Month Complication Log

The single strongest piece of evidence for a 7.18 case is a well documented complication log. Every complication episode should include the date, the type of complication, the duration in days, the medical care needed, and the impact on daily functioning. Draw the log from actual medical records rather than from memory. Sources include hospital admission records, ER records, urgent care visits, home health notes, transfusion service records, oncology visit notes, hematology follow up notes, and pharmacy records showing rescue medication use.

The log should span the entire relevant period, not just the last 12 months. If your worst year was 2024 and you filed in 2026, the 2024 events count. Section 7.00G3 explicitly allows this.

Worked Case Examples

Case One, Renee, 47, Michigan

Renee has pernicious anemia diagnosed in 2020 after presenting with megaloblastic anemia, ataxia, and cognitive complaints. Serum B12 was 82 pg per mL, methylmalonic acid was 1,240 nmol per L, intrinsic factor antibodies were positive. MRI spine showed T2 hyperintensity in the posterior columns consistent with subacute combined degeneration. She receives monthly IM cyanocobalamin injections and hemoglobin normalized within six months. However, her ataxia and cognitive slowing persisted. Neuropsych testing in 2023 documented processing speed at the fifth percentile and working memory at the tenth percentile. She has fallen four times in 12 months and cannot cook a meal without setting timers on every step. Functional limitations reach marked in ADLs and concentration. Complications include four falls with two ER visits, three hemolytic transfusion reactions from earlier care, and two episodes of pancytopenia from concurrent H pylori gastritis in the past three years. Listing 7.18 is met.

Case Two, Terrance, 62, Georgia

Terrance has MDS with multilineage dysplasia, IPSS-R low risk, transfusion dependent since 2024. He requires two units of packed red blood cells every three to four weeks and takes deferasirox for iron chelation. Ferritin is 3,800 despite chelation. He has had four febrile episodes in the past 12 months requiring outpatient antibiotics, two hospitalizations for pneumonia, and chronic fatigue that keeps him in bed 20 hours a day between transfusions. Functional limitation reaches marked in ADLs. Complications include two hospitalizations, four febrile events lasting more than one week each, and cyclical fatigue crises after every transfusion cycle. Listing 7.18 is met.

Case Three, Nina, 34, Arizona

Nina has warm antibody autoimmune hemolytic anemia diagnosed in 2022. She has been through prednisone, rituximab, splenectomy, and mycophenolate. Hemoglobin ranges from 7.5 to 9.8. She had four hemolytic flares in the past 24 months, each lasting 10 to 14 days, requiring pulsed steroids and one transfusion. She has chronic fatigue and dyspnea on mild exertion. She had a DVT related to steroids in 2024. Functional limitation reaches marked in ADLs and social functioning because she cannot maintain regular interactions during flares. Complications total four flares plus one DVT plus two transfusion reactions across 24 months. Listing 7.18 is met.

Documentation Package That Wins 7.18 Cases

• Diagnosis confirmation with pathology, laboratory, or genetic testing as appropriate to the specific disorder.
• CBC trends across the entire relevant period.
• Peripheral smear reports, bone marrow biopsy reports, and cytogenetic or molecular testing when relevant.
• All hospitalization records, ER records, and urgent care records.
• Transfusion service records with dates and units.
• Treatment records for all agents including chemotherapy, immunosuppression, complement inhibitors, TPO agonists, iron chelation, and stem cell mobilization if performed.
• Functional statements from primary care, hematology, and any specialists documenting how the disease affects daily activities.
• Neuropsych testing when cognitive complaints are prominent, particularly for B12 deficiency, chronic anemia, and post transplant patients.
• Third party function reports from a family member describing your ability to cook, clean, drive, and maintain social contact.

Denial Counters

Denial reason: complications not frequent enough

The analyst may have counted only the last 12 months. Response is to point to Section 7.00G3 which considers the entire relevant period and the three way frequency and duration test. Complications lasting substantially longer than two weeks satisfy the rule even when they occur less than three times per year.

Denial reason: no marked limitation documented

The analyst may have missed functional evidence. Response is to add third party function reports from family and coworkers, add neuropsych testing when fatigue and cognitive slowing are present, and get a hematology attending statement addressing the three specific functional areas by name.

Denial reason: hematological disorder well controlled on treatment

Treatment side effects count toward functional limitation under Section 7.00G4. If eculizumab prevents your PNH thrombosis but you still have chronic fatigue and infusion reactions, those still support marked limitation.

Denial reason: complications not caused by hematological disorder

The analyst may have attributed events to comorbidities. Response is to document the causal chain. For example, a fall with a hip fracture in an aplastic anemia patient with severe thrombocytopenia is a hematological complication because the bleeding risk drove the injury outcome.

Interaction With Other Listings

Section 7.18 is often the primary claim, but many hematology patients also meet other listings by combination. Sickle cell patients with avascular necrosis of the hip may meet Listing 1.18 for major joint dysfunction. Chronic anemia with heart failure may meet Listing 4.02. Post transplant patients may meet Listing 7.17 automatically for 12 months after transplantation. B12 deficiency with peripheral neuropathy may add Listing 11.14. Cases are strongest when the analyst has multiple listing paths to consider.

SSDI Versus SSI for Hematology Claimants

Hematological disorders often disable people at younger ages who may have limited work history. Fanconi anemia, Diamond Blackfan anemia, and sickle cell disease diagnosed in childhood often prevent enough work quarters for SSDI insured status. In those cases, Supplemental Security Income under 20 CFR 416 provides an alternate benefit path with the same medical rules. SSA applies the same 7.18 criteria in SSI cases as in SSDI cases. Income and resource limits govern SSI eligibility on the non medical side. The 2026 Federal Benefit Rate for SSI is 967 dollars per month for an eligible individual.

State Considerations

Hematology cases move at very different speeds depending on where you file. See our state pages for high volume jurisdictions including California, Texas, Florida, New York, and Illinois. Rare disease diagnoses often benefit from filing near major academic centers with strong subspecialty coverage.

Related Blog Articles

• Listing 7.08 Disorders of Thrombosis and Hemostasis for hemophilia and thrombocytopenia claims that fit a hospitalization-count structure.
• Listing 14.07 Immune Deficiency Disorders for cases with combined immune and hematologic features.
• Listing 5.02 Chronic GI Hemorrhage for the transfusion counting rule in a different body system.

Frequently Asked Questions